kcl22 s acc519 cell lines  (DSMZ)

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: CML‐derived cell lines. In particular, name of cell line, cell type, sex and age of patient at time of establishment of cell line, disease status, year of establishment of cell line, source of specimen as indicated in the original publication and type of BCR,ABL1 fusion are indicated (BC = blastic crisis, BCP = B‐Cell Precursor, B‐LCL = B‐lymphoblastoid cell line (EBV + ), BM = bone marrow, BMT = bone marrow transplantation, F = female, M = male, NA = not available, R = relapse, PB = peripheral blood, PE = pleural effusion).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Transplantation Assay

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating the seven different treatment conditions of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: DMSO at 20X zoom in the three cell lines; Panel C1, C2, C3: imatinib at 20× zoom in the three cell lines; Panel D1, D2, D3: nilotinib at 20× zoom in the three cell lines; Panel E1, E2, E3: dasatinib at 20× zoom in the three cell lines; Panel F1, F2, F3: bosutinib at 20× zoom in the three cell lines; Panel G1, G2, G3: ponatinib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells; blue boxes highlight apoptotic bodies. (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Imaging, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from each treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (BOSU, bosutinib; CTR, control; DASA, dasatinib; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; PONA, ponatinib; TKIs, tyrosine kinase inhibitors). (Two Way ANOVA).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cells viability (%) measured by MTT assay in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: MTT Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Number of cells measured by CCK8 assay in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: CCK-8 Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Extracellular glutamate concentration (μM) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA: imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Concentration Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of BCR::ABL1 transcript (normalised for GAPDH) in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD33 transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD11b transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating asciminib treatment of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: asciminib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells. (CTR, control; ASCI, asciminib).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Imaging, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from asciminib treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (ASCI, asciminib; CTR, control). (Two Way ANOVA).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cell viability (%) measured by MTT assay (A), number of cells measured by CCK8 assay (B), extracellular glutamate concentration (μM) (C) and expression of BCR::ABL1 (D), CD33 (E) and CD11b (F) transcripts all normalized for GAPDH in the three cell lines considered, K562, LAMA84 and KCL22, following asciminib treatment. (CTR, control; ASCI, asciminib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: MTT Assay, CCK-8 Assay, Concentration Assay, Expressing, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: CML‐derived cell lines. In particular, name of cell line, cell type, sex and age of patient at time of establishment of cell line, disease status, year of establishment of cell line, source of specimen as indicated in the original publication and type of BCR,ABL1 fusion are indicated (BC = blastic crisis, BCP = B‐Cell Precursor, B‐LCL = B‐lymphoblastoid cell line (EBV + ), BM = bone marrow, BMT = bone marrow transplantation, F = female, M = male, NA = not available, R = relapse, PB = peripheral blood, PE = pleural effusion).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Transplantation Assay

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating the seven different treatment conditions of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: DMSO at 20X zoom in the three cell lines; Panel C1, C2, C3: imatinib at 20× zoom in the three cell lines; Panel D1, D2, D3: nilotinib at 20× zoom in the three cell lines; Panel E1, E2, E3: dasatinib at 20× zoom in the three cell lines; Panel F1, F2, F3: bosutinib at 20× zoom in the three cell lines; Panel G1, G2, G3: ponatinib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells; blue boxes highlight apoptotic bodies. (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Imaging, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from each treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (BOSU, bosutinib; CTR, control; DASA, dasatinib; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; PONA, ponatinib; TKIs, tyrosine kinase inhibitors). (Two Way ANOVA).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cells viability (%) measured by MTT assay in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: MTT Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Number of cells measured by CCK8 assay in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: CCK-8 Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Extracellular glutamate concentration (μM) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA: imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Concentration Assay, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of BCR::ABL1 transcript (normalised for GAPDH) in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD33 transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD11b transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Expressing, Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating asciminib treatment of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: asciminib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells. (CTR, control; ASCI, asciminib).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Imaging, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from asciminib treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (ASCI, asciminib; CTR, control). (Two Way ANOVA).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: Comparison, Control

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cell viability (%) measured by MTT assay (A), number of cells measured by CCK8 assay (B), extracellular glutamate concentration (μM) (C) and expression of BCR::ABL1 (D), CD33 (E) and CD11b (F) transcripts all normalized for GAPDH in the three cell lines considered, K562, LAMA84 and KCL22, following asciminib treatment. (CTR, control; ASCI, asciminib) (Two‐way ANOVA with Tukey's post hoc test).

Article Snippet: Specifically, K562 cells were derived from the pleural effusion of a 53‐year‐old woman during BC, LAMA84 cells originated from the peripheral blood of a 29‐year‐old woman who had previously undergone 5 years of busulfan treatment, and KCL22 cells were isolated from the pleural effusion of a 32‐year‐old woman experiencing BC ( https://www.Dsmz.de/Collection/Catalogue/Human-and-Animal-Cell-Lines/Catalogue ).

Techniques: MTT Assay, CCK-8 Assay, Concentration Assay, Expressing, Control